In particular, B cell depletion with the anti-CD20 antibody rituximab seems to work for RA patients resistant to standard disease-modifying antirheumatic drugs (DMARDs) and tumor necrosis factor ...

and will enter an increasingly competitive market in which Roche has been setting the pace recently with Ocrevus (ocrelizumab), an anti-CD20 drug which has already become a blockbuster following ...

An additional anti-CD20 antibody fragment directly targets the cancer. By design, the molecule possesses an interleukin-2 variant that triggers natural killer cell proliferation without activating ...

However, she reckons it will still trail Roche's first-to-market anti-CD20 drug Ocrevus (ocrelizumab), even though that drug needs to be administered by intravenous infusion. While it requires a ...

“Anti-CD20 antibodies have demonstrated the ability ... the initial success of this drug (Nature Rev. Immunol. 6, 394–403; 2006) has led to its evaluation in other autoimmune diseases.

and includes discussion of the drug's potential role in novel therapeutic protocols. Rituximab, a monoclonal antibody directed against CD20, has been successfully used in hematological B-cell ...

Science, 2020 To support CD20 antibody drug development ... CD20 proteins feature both big and small ECD loops and bind anti-CD20 antibodies with high binding affinity in SPR and ELISA assay.

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

SHANGHAI--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat ... antibodies such as rituximab (anti-CD20 mAb) is an established treatment ...